|
JP2003511378A
(ja)
|
1999-10-07 |
2003-03-25 |
アムジエン・インコーポレーテツド |
トリアジン系キナーゼ阻害薬
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
WO2001034119A2
(en)
|
1999-11-12 |
2001-05-17 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
|
HUP0301117A3
(en)
|
2000-02-17 |
2004-01-28 |
Amgen Inc Thousand Oaks |
Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
|
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
IL157608A0
(en)
|
2001-02-27 |
2004-03-28 |
Teva Pharma |
New crystal forms of lamotrigine and processes for their preparations
|
|
MXPA03011784A
(es)
|
2001-06-22 |
2004-04-02 |
Pfizer Prod Inc |
Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
|
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
DK1438053T3
(da)
|
2001-10-17 |
2008-12-08 |
Boehringer Ingelheim Pharma |
Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US7375222B2
(en)
|
2002-02-05 |
2008-05-20 |
Astellas Pharma Inc. |
2,4,6-Triamino-1,3,5-triazine derivative
|
|
AU2003234240A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing lamotrigine particles of defined morphology
|
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
|
US7015227B2
(en)
|
2002-06-21 |
2006-03-21 |
Cgi Pharmaceuticals, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
BR0313059B8
(pt)
|
2002-07-29 |
2021-07-27 |
Rigel Pharmaceuticals |
composto, e, composição farmacêutica
|
|
CN102702111B
(zh)
|
2002-08-09 |
2014-12-17 |
詹森药业有限公司 |
制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
|
|
DK1551372T3
(en)
*
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
|
KR20050084027A
(ko)
*
|
2002-11-28 |
2005-08-26 |
쉐링 악티엔게젤샤프트 |
Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
|
|
AU2002350719A1
(en)
|
2002-11-29 |
2004-06-23 |
Janssen Pharmaceutica N.V. |
Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
|
|
CN102558155A
(zh)
|
2003-01-14 |
2012-07-11 |
阿伦纳药品公司 |
作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
|
|
PL227577B1
(pl)
*
|
2003-02-07 |
2017-12-29 |
Janssen Pharmaceutica Nv |
Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
|
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
CN1822843B
(zh)
|
2003-07-17 |
2010-04-28 |
泰博特克药品有限公司 |
制备含有抗病毒药物颗粒的方法
|
|
CN102358738A
(zh)
|
2003-07-30 |
2012-02-22 |
里格尔药品股份有限公司 |
2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
KR20060123164A
(ko)
|
2003-10-17 |
2006-12-01 |
아스트라제네카 아베 |
암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
|
|
ES2391636T3
(es)
|
2004-03-05 |
2012-11-28 |
F. Hoffmann-La Roche Ag |
Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
|
|
MX2007003327A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
|
|
EP1799667B1
(en)
|
2004-09-20 |
2013-03-20 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
EP2269610A3
(en)
|
2004-09-20 |
2011-03-09 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
MX2007003332A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
|
|
JP4958786B2
(ja)
|
2004-09-20 |
2012-06-20 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
複素環誘導体および治療薬としてのそれらの使用
|
|
MX2007003319A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como agentes terapeuticos.
|
|
JP5095409B2
(ja)
|
2004-11-24 |
2012-12-12 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
スピロ２，４−ピリミジンジアミン化合物およびその使用
|
|
JP4801096B2
(ja)
|
2005-01-19 |
2011-10-26 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
|
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
|
JP5247154B2
(ja)
*
|
2005-02-18 |
2013-07-24 |
テイボテク・フアーマシユーチカルズ |
Ｈｉｖ阻害性２−（４−シアノフェニルアミノ）ピリミジンオキシド誘導体
|
|
PT1858861E
(pt)
*
|
2005-03-04 |
2010-09-16 |
Tibotec Pharm Ltd |
2-(4-cianofenil)-6-hidroxilaminopirimidinas inibidoras do hiv
|
|
AR056652A1
(es)
|
2005-04-11 |
2007-10-17 |
Tibotec Pharm Ltd |
Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
|
|
JP2008540622A
(ja)
|
2005-05-16 |
2008-11-20 |
アストラゼネカ アクチボラグ |
化合物
|
|
ES2437202T3
(es)
*
|
2005-05-26 |
2014-01-09 |
Janssen R&D Ireland |
Procedimiento para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)-amino]benzonitrilo
|
|
BRPI0611187A2
(pt)
|
2005-06-03 |
2010-08-24 |
Xenon Pharmaceuticals Inc |
derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
|
|
WO2007025901A1
(en)
|
2005-09-01 |
2007-03-08 |
F. Hoffmann-La Roche Ag |
Diaminopyrimidines as p2x3 and p2x2/3 modulators
|
|
ES2612890T3
(es)
|
2005-09-01 |
2017-05-19 |
F. Hoffmann-La Roche Ag |
Diaminopirimidinas como moduladores de P2X3 y P2X2/3
|
|
JP4850912B2
(ja)
|
2005-09-01 |
2012-01-11 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
|
|
WO2007049041A1
(en)
|
2005-10-28 |
2007-05-03 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
|
CN101299993A
(zh)
*
|
2005-11-04 |
2008-11-05 |
伊士曼化工公司 |
用于给药难溶的药学活性剂的羧烷基纤维素酯
|
|
BRPI0712346B8
(pt)
*
|
2006-06-06 |
2021-05-25 |
Janssen R & D Ireland |
processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica
|
|
KR101486228B1
(ko)
|
2006-06-19 |
2015-01-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
|
CA2665726C
(en)
*
|
2006-10-11 |
2016-04-19 |
Alpharma, Inc. |
Pharmaceutical compositions
|
|
JP5464584B2
(ja)
*
|
2006-12-06 |
2014-04-09 |
ヤンセン・アールアンドデイ・アイルランド |
抗ｈｉｖ化合物の臭化水素酸塩
|
|
AR065720A1
(es)
*
|
2007-03-14 |
2009-06-24 |
Tibotec Pharm Ltd |
Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
DK2155169T3
(en)
*
|
2007-06-08 |
2016-06-13 |
Boehringer Ingelheim Int |
Formulation of nevirapine extended release
|
|
CN101790371A
(zh)
*
|
2007-06-25 |
2010-07-28 |
泰博特克药品公司 |
包含达芦那韦和依曲韦林的组合制剂
|
|
EP2212298B1
(en)
*
|
2007-10-18 |
2013-03-27 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
|
US7982036B2
(en)
|
2007-10-19 |
2011-07-19 |
Avila Therapeutics, Inc. |
4,6-disubstitued pyrimidines useful as kinase inhibitors
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
US20090196890A1
(en)
*
|
2007-12-17 |
2009-08-06 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical compositions
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
ES2439009T3
(es)
*
|
2008-08-20 |
2014-01-21 |
Merck Sharp & Dohme Corp. |
Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
|
|
TW201020245A
(en)
*
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
|
WO2010033226A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
|
CN101744823B
(zh)
*
|
2008-12-17 |
2013-06-19 |
广东东阳光药业有限公司 |
一种二氢嘧啶类化合物的固体分散体及其药用制剂
|
|
BRPI1012666B8
(pt)
|
2009-03-30 |
2021-05-25 |
Janssen R&D Ireland |
cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
|
|
WO2010144345A1
(en)
*
|
2009-06-08 |
2010-12-16 |
Abraxis Bioscience, Llc |
Triazine derivatives and their therapeutical applications
|
|
US20110196156A1
(en)
*
|
2009-06-22 |
2011-08-11 |
Mukund Keshav Gurjar |
Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
|
|
US8354420B2
(en)
|
2010-06-04 |
2013-01-15 |
Genentech, Inc. |
Aminopyrimidine derivatives as LRRK2 inhibitors
|
|
MX2013003184A
(es)
|
2010-09-22 |
2013-06-07 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
|
|
SI2638031T1
(en)
|
2010-11-10 |
2018-02-28 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
EP2836559B1
(en)
*
|
2012-04-11 |
2016-05-25 |
Dow Global Technologies LLC |
Composition comprising an organic diluent and a cellulose ether
|
|
JP5731723B2
(ja)
*
|
2012-04-11 |
2015-06-10 |
ダウ グローバル テクノロジーズ エルエルシー |
セルロースエーテルを含む溶融押出し組成物
|
|
EP2836235B1
(en)
*
|
2012-04-11 |
2017-03-08 |
Dow Global Technologies LLC |
Novel sustained release dosage forms
|
|
LT3495367T
(lt)
|
2012-06-13 |
2021-02-25 |
Incyte Holdings Corporation |
Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
|
|
WO2014009968A2
(en)
*
|
2012-07-12 |
2014-01-16 |
Hetero Research Foundation |
Process for rilpivirine using novel intermediate
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
SG11201706287PA
(en)
|
2015-02-20 |
2017-09-28 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
AR100459A1
(es)
*
|
2015-05-15 |
2016-10-05 |
Química Luar S R L |
Una composición farmacéutica antiviral de uso tópico
|
|
PL3310760T3
(pl)
|
2015-06-22 |
2023-03-06 |
Arena Pharmaceuticals, Inc. |
Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
|
|
KR20190116416A
(ko)
|
2017-02-16 |
2019-10-14 |
아레나 파마슈티칼스, 인크. |
원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
|
|
WO2018187652A1
(en)
|
2017-04-06 |
2018-10-11 |
Janssen Pharmaceutica Nv |
2,4-diaminopyrimidine derivatives as histamine h4 modulators
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
MX2020011718A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
|
|
ES3061844T3
(en)
|
2018-05-04 |
2026-04-07 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
AU2019280822A1
(en)
|
2018-06-06 |
2021-01-07 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11166952B2
(en)
|
2019-11-29 |
2021-11-09 |
Aptorum Therapeutics Limited |
Composition including rilpivirine and method for treating tumors or cancer
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR102145925B1
(ko)
|
2020-03-03 |
2020-08-19 |
협동조합 바이오융합기술 |
사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
|
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
CN116425683A
(zh)
*
|
2023-04-04 |
2023-07-14 |
上药康丽（常州）药业有限公司 |
一种米诺地尔的合成精制方法
|